secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001628280-24-030708
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment
-------------------------------------------------------------------

- Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.
- Decision aimed at preserving patient access to the phosphate absorption inhibitor.
- By opting out, XPHOZAH will not receive transitional add-on payment from Medicare.
- Announcement made on July 2, 2024; no financial guidance provided on impact.
- Company expects to rely on standard ESRD PPS bundled payment for XPHOZAH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024030708/0001628280-24-030708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828024030708/ardx-20240702.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-030708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer